GlaxoSmithKline (GSK) Given Neutral Rating at BNP Paribas

BNP Paribas restated their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a research report report published on Thursday. BNP Paribas currently has a GBX 1,560 ($21.55) price target on the stock.

Several other analysts have also commented on GSK. Morgan Stanley upgraded shares of GlaxoSmithKline from an underweight rating to an equal rating and raised their price objective for the stock from GBX 1,300 ($17.96) to GBX 1,400 ($19.34) in a report on Thursday. Societe Generale restated a sell rating and issued a GBX 1,130 ($15.61) price objective on shares of GlaxoSmithKline in a report on Wednesday, March 14th. Liberum Capital restated a buy rating and issued a GBX 1,630 ($22.52) price objective on shares of GlaxoSmithKline in a report on Thursday, March 8th. Goldman Sachs set a GBX 1,750 ($24.18) price objective on shares of GlaxoSmithKline and gave the stock a buy rating in a report on Friday, March 2nd. Finally, HSBC restated a buy rating and issued a GBX 1,925 ($26.60) price objective on shares of GlaxoSmithKline in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of GBX 1,529.55 ($21.13).

How to Become a New Pot Stock Millionaire

Shares of GlaxoSmithKline stock opened at GBX 1,315.60 ($18.18) on Thursday. The stock has a market capitalization of $65,630.00 and a PE ratio of 2,482.26. GlaxoSmithKline has a 12 month low of GBX 1,235.20 ($17.07) and a 12 month high of GBX 1,724.50 ($23.83).

The firm also recently announced a dividend, which will be paid on Thursday, April 12th. Stockholders of record on Thursday, February 22nd will be issued a dividend of GBX 23 ($0.32) per share. This represents a dividend yield of 1.78%. This is a positive change from GlaxoSmithKline’s previous dividend of $19.00. The ex-dividend date is Thursday, February 22nd.

In related news, insider Patrick Vallance sold 14,022 shares of the firm’s stock in a transaction that occurred on Monday, February 19th. The shares were sold at an average price of GBX 1,318 ($18.21), for a total transaction of £184,809.96 ($255,332.91). Also, insider Sir Roy Anderson purchased 562 shares of GlaxoSmithKline stock in a transaction that occurred on Wednesday, February 7th. The shares were purchased at an average cost of GBX 1,278 ($17.66) per share, with a total value of £7,182.36 ($9,923.13). Over the last quarter, insiders have bought 591 shares of company stock valued at $756,678 and have sold 23,765 shares valued at $31,152,709.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3300779/glaxosmithkline-gsk-given-neutral-rating-at-bnp-paribas.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

STEX  Hits Market Cap of $0.00
STEX Hits Market Cap of $0.00
NVO  Price Down 26.6% This Week
NVO Price Down 26.6% This Week
SunTrust Banks Increases Heidrick & Struggles  Price Target to $35.00
SunTrust Banks Increases Heidrick & Struggles Price Target to $35.00
Alphabet  Receives “Overweight” Rating from KeyCorp
Alphabet Receives “Overweight” Rating from KeyCorp
Alphabet  PT Lowered to $970.00
Alphabet PT Lowered to $970.00
Statoil  Announces Quarterly Dividend of $0.23
Statoil Announces Quarterly Dividend of $0.23


© 2006-2018 Ticker Report. Google+.